免疫疗法
癌症研究
免疫系统
癌症免疫疗法
化学
受体
肿瘤微环境
细胞生物学
髓样
免疫学
免疫检查点
生物
渗透(HVAC)
癌症
甘露糖受体
癌细胞
髓系细胞
重编程
免疫分型
半乳糖凝集素
先天免疫系统
作者
Ting Pan,Jiaqi Wu,Tingting Wang,Heping Wang,Bo Zeng,Yangyang Li,Ming Yi,Ruirui He,Lingyun Feng,Zhihui Cui,Guoling Huang,Panyin Shu,Xi Li,Yuan Wang,Yanyun Du,Zhen Li,Xue Xiao,Ce Wang
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2026-11-19
标识
DOI:10.1158/0008-5472.can-26-2612
摘要
Resistance to PD-1–based immunotherapy remains a major challenge in cancer treatment, especially in immunologically “cold” tumors characterized by T-cell exclusion and impaired T-cell effector function. Mechanical processes impact T-cell activity, and mechanical perturbations may represent a distinct mode of immune suppression. Here, we identified CD209, a myeloid-expressed C-type lectin receptor, as a mechanosuppressive regulator of antitumor T-cell immunity. CD209 was selectively enriched in tumor-infiltrating M2-like macrophages and monocytes, and elevated CD209 expression was associated with poor clinical response to PD-1 blockade and immune dysfunction and exclusion across multiple cancer types. Mechanistically, CD209 directly engaged ICAM-2 on T cells and activated ROCK1–ERM signaling. This interaction increased T-cell cortical stiffness, destabilized T cell–antigen presenting cell interactions, and attenuated T-cell receptor signaling. Blocking the CD209–ICAM-2–ERM pathway restored T-cell activation and promoted CD8+ T-cell infiltration and effector function in both in vivo mouse models and ex vivo human tumor systems. Importantly, CD209 blockade enhanced the response to PD-1 inhibition and overcame resistance to PD-1–based immunotherapy in refractory and immunologically “cold” tumor models. Together, these findings define a myeloid-derived mechanical immune checkpoint and reveal T-cell mechanosuppression as a targetable mechanism of tumor immune evasion and immunotherapy resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI